News

QurAlis reports ANQUR interim data for ALS therapy QRL-201 at NEALS 2026

What happened: At the 2026 Northeast ALS Consortium (NEALS) annual meeting (27-30 October 2026), QurAlis reported interim data from ANQUR, the Phase 1 trial of QRL-201, an investigational therapy for amyotrophic lateral sclerosis (ALS, also known as motor neurone disease). QRL-201 is an antisense oligonucleotide — a short, lab-made piece of genetic material designed to correct a common splicing defect in the STMN2 gene implicated in ALS. The data showed the drug distributed broadly across the spinal cord and motor cortex, engaged its target, corrected the mis-splicing and raised STMN2 protein levels above the estimated therapeutic threshold, all with statistically significant results. In the dose-range-finding phase, patients on the low dose showed a statistically significant reduction in neurofilaments — a biomarker of nerve damage — and a trend toward slower loss of function. In a post-hoc analysis excluding the fastest-progressing patients, sporadic ALS patients showed a statistically significant, clinically meaningful slowing of functional decline at 26 weeks, measured on the ALSFRS-R scale.

Why it matters: ALS is a rapidly progressive disease in which motor neurons die, leading to paralysis and usually death within a few years; current therapies only modestly slow progression. QRL-201 targets a specific genetic defect thought to drive the disease in many patients. QurAlis says the data support advancing the drug into a pivotal Phase 3 trial in 2027, with an open-label extended-dosing period already approved in Canada and under regulatory review in the UK and EU. The drug was generally safe and well tolerated in the trial, with most side effects mild to moderate.

Read more: NeurologyLive, 5 November 2026

More top stories